ScreenerHero

PHILPhilogen SpA

BIT · IT · Healthcare · Biotechnology · philogen.com
23.35EUR-0.85%Mkt Cap: 1.03B $P/E: 4.13

Philogen S.p.A., a biotechnology company, engages in the research and development of drugs for oncology and chronic inflammatory diseases in Italy, Switzerland, the United States, and the European Union. The company deve…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap1.03B $
Enterprise Value626.42M $
Revenue (TTM)347.53M $
Gross Profit335.89M $
Net Income (TTM)249.65M $
Revenue/Share8.629 USD
Last Price23.35 EUR
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees214
CountryIT
SectorHealthcare
IndustryBiotechnology
ISINIT0005373789
Valuation
P/E (Trailing)4.13
P/E (Forward)-58.24
PEG—
EV/EBITDA2.22
EV/Revenue1.80
P/S2.95
P/B2.53
EPS (TTM)5.70
EPS (Forward)-0.40
52W Range
19.5659% of range26.00
52W High26.00 EUR
52W Low19.56 EUR
Profitability
Gross Margin98.31%
Oper. Margin87.72%
EBITDA Margin81.35%
Profit Margin73.07%
ROE61.43%
ROA52.52%
Growth
Revenue Growth310.80%
Earnings Growth300.10%
Cash Flow & Leverage
Operating CF291.27M $
CapEx (TTM)3.95M $
FCF Margin63.04%
FCF Yield21.26%
Net Debt-400.32M $
Net Debt/EBITDA-1.42
Balance Sheet
Debt/Equity0.03
Current Ratio7.76
Quick Ratio7.69
Book Value/Sh9.281 EUR
Cash/Share9.414 EUR
Dividends
Fwd Div Rate0.7000 EUR
Trail. Div Rate0.7000 EUR
Div. Yield2.99%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateMay 18, 2026
Pay Date—
Analyst Consensus
Rating1.7 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)27.67 EUR
Upside (mean)+18.5%
Target Range19.00 EUR – 34.00 EUR
€19.00+18.5% to mean€34.00
# Analysts3
Ownership
Shares Out.28.88M
Float10.75M
Insiders62.15%
Institutions9.09%
Technical
SMA 5023.82 (-2.0%)
SMA 20022.61 (+3.3%)
Beta-0.02
S&P 52W Chg19.18%
Avg Vol (30d)21.45K
Avg Vol (10d)20.99K
Technical Indicators
RSI (14)47.9
MACD-0.0176
MACD Signal-0.0244
MACD Hist.+0.0068
BB Upper24.46 EUR
BB Middle23.67 EUR
BB Lower22.89 EUR
BB Width6.62%
ATR (14)0.7380 EUR
Vol Ratio (20d)1.96x